Mark H. Mirkin


.(JavaScript must be enabled to view this email address)
(919) 241-7495


Duke University

J.D., 1984

Duke University

B.A., cum laude, 1981

Previous Experience

  • Hicks, Motto & Ehrlich (Partner)


  • State of Florida
  • State of North Carolina

Professional Experience

Mark Mirkin focuses his practice on strategic corporate and securities counseling to emerging and high-growth companies, especially in the context of seed, early stage and venture capital financings, mergers and acquisitions, divestitures and IPOs.  He has applied his voluminous knowledge of the startup landscape to help his clients in early stage financing transactions, particularly in private placements and public offerings of equity, debt and convertible securities. In this capacity, he has extensive experience advising companies in the life sciences, information technology, and clean technology industries in all aspects of corporate and securities law.  

Mr. Mirkin has represented numerous biotech and medtech startups in launching their drug discoveries and medical devices, helping to navigate them through the FDA clinical trial process for new drug approval and to surmount the regulatory hurdles for medical devices. Many such companies have been spin-outs from universities' and research institutions' laboratories, benefiting along with infotech startups from Mr. Mirkin's extensive experience in the technology transfer process.

Prior to joining Rimon, Mr. Mirkin worked as a partner at Hicks, Motto & Ehrlich in Palm Beach Gardens, Florida. He has been a frequent speaker to university audiences of engineering, computer science and medical students on topics of corporate and securities law, especially venture financing for technology startups. He was honored to chair the inaugural Southeast Venture Conference. 

Mr. Mirkin received his J.D. from Duke Law School and his B.A. in Economics cum laude from Duke University.

Representative Matters

  • Represented several group medical practices in acquisitions, both on buy and sell side, both to public and private buyers
  • Represented an offshore medical device company with commencement of U.S. clinical trials for FDA clearance
  • Represented a leading distributor of dietary supplements in a $75 million dollar securities offering
  • Represented a medical device university spin-out in its acquisition by a private equity firm
  • Represented an international combination medical device and laboratory services company in a venture capital financing
  • Represented an esoteric beverages company in an angel financing in Europe
  • Represented a nutritional supplements company in a strategic reorganization followed by a private equity financing
  • Represented the Compensation Committee of the Board of Directors of a publicly-traded company selling a line of assets to a Fortune 50 acquirer